Du, Xiaohui; Kim, Yong-Jae; Lai, SuJen; Chen, Xi; Lizarzaburu, Mike; Turcotte, Simon; Fu, Zice; Liu, Qingxiang; Zhang, Ying; Motani, Alykhan; Oda, Kozo; Okuyama, Ryo; Nara, Futoshi; Murakoshi, Michiko; Fu, Angela; Reagan, Jeff D.; Fan, Peter; Xiong, Yumei; Shen, Wang; Li, Leping; Houze, Jonathan; Medina, Julio C. published the artcile< Phenylalanine derivatives as GPR142 agonists for the treatment of Type II diabetes>, Safety of (9Z,12Z)-Methyl octadeca-9,12-dienoate, the main research area is phenylalanine derivative preparation GPR142 agonists NIDDM diabetes.
GPR142 is a novel GPCR that is predominantly expressed in pancreatic β-cells. GPR142 agonists potentiate glucose-dependent insulin secretion, and therefore can reduce the risk of hypoglycemia. Optimization of our lead pyridinone-phenylalanine series led to a proof-of-concept compound 22, which showed in vivo efficacy in mice with dose-dependent increase in insulin secretion and a decrease in glucose levels.
Bioorganic & Medicinal Chemistry Letters published new progress about Antidiabetic agents. 112-63-0 belongs to class esters-buliding-blocks, and the molecular formula is C19H34O2, Safety of (9Z,12Z)-Methyl octadeca-9,12-dienoate.
Referemce:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics